Xolair 300 MG/2 ML autoinject 2ML
Ended Awarded Last action
- Contract number
- SPE2DR26FSHE4
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $13,980
Award facts
- Contract value 100% obligated
- $13,979.52 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Park Ridge, IL 60068, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a $13,979.52 firm fixed-price delivery order to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler based in Park Ridge, Illinois, for the supply of Xolair 300 mg/2 ml autoinjector units. The delivery order, issued on January 30, 2026, with an ultimate completion date of February 23, 2026, carries no set-aside designation, indicating the award was made through open competition. This delivery order is issued under DMS Pharmaceutical Group's single-award Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a comprehensive $30.3 billion acquisition strategy designed to supply pharmaceutical products to Department of Defense healthcare facilities worldwide.
DMS Pharmaceutical Group has demonstrated substantial capability as a federal pharmaceutical supplier, with the parent IDC featuring a $499.999 billion ceiling value and extending through December 31, 2036. The company's established performance across multiple delivery orders encompassing diverse pharmaceutical categories—including biologics such as Xolair, specialty medications, vaccines, and medical consumables—positions it as a critical supplier within the federal military medical supply chain. As a woman-owned small business registered in the System for Award Management since 2001, DMS Pharmaceutical Group competes effectively in unrestricted federal pharmaceutical procurement while supporting the Department of Defense's global healthcare operations.
Quick answers
Who was awarded contract SPE2DR26FSHE4?
SPE2DR26FSHE4 was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on January 30, 2026.
How much is contract SPE2DR26FSHE4 worth?
The government has obligated $13,980 on SPE2DR26FSHE4.
Is contract SPE2DR26FSHE4 an order under another contract?
Yes. SPE2DR26FSHE4 is a delivery order under SPE2DR25D9305, an indefinite delivery contract.
Was contract SPE2DR26FSHE4 competed?
The extent of competition for SPE2DR26FSHE4 was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award